Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Laekna’s jumping off place

Why Laekna Therapeutics opted to start with a trio of Novartis compounds

Chinese biotech Laekna Therapeutics Shanghai Co. Ltd. is jump-starting its pipeline with a trio of clinical cancer compounds from Novartis AG. The safety of the lead candidate and its potential to synergize with the other two could give Laekna an advantage in castration-resistant prostate cancer.

CEO Chris Lu was head of discovery biology and technologies at Novartis before founding Laekna in 2016. He told BioCentury the biotech’s aim is to build a portfolio of internally discovered

Read the full 762 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers